The 144 filing signals intent to sell but the amount is small and routine for a CEO. Monitor whether the sale actually executes on Form 4; if it does, watch for any pattern of larger sales in subsequent filings.
TARS drugs
TARS drug pipeline →Price Chart
How similar events traded
Executive Summary
CEO Bobak Azamian filed a Form 144 notice of intent to sell 10,000 shares of Tarsus Pharmaceuticals common stock, with an approximate market value of $801,500 based on the filing date. The shares were acquired in a private placement in 2017 and are held through the Bobak Azamian Living Trust. The sale is small relative to the CEO's likely total holdings and the company's $3.8B market cap, representing about 0.02% of shares outstanding.
Key Facts
- CEO Bobak Azamian filed Form 144 to sell 10,000 shares of common stock
- Estimated proceeds of ~$801,500 based on filing date
- Shares acquired via private placement on 01/13/2017
- Shares held through the Bobak Azamian Living Trust
- Sale represents a small fraction of CEO's holdings and ~0.02% of shares outstanding
Financial Impact
~$801,500 sale, ~0.02% of shares outstanding, ~0.02% of market cap
Risk Factors
- Insider selling could signal lack of confidence if it becomes a pattern
- Form 144 is only an intent to sell; the sale may not occur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-073909 |
| Document: 0001628280-26-073909-index.html | 0001628280-26-073909 |
| Document: 0001628280-26-073909.txt | 0001628280-26-073909 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers